PFIZER INC.

Halozyme Therapeutics offers €2 billion to acquire Evotec SE, aiming to combine Halozyme’s drug delivery expertise with Evotec’s drug discovery capabilities, accelerating biologic drug development and expanding global access to affordable treatments. The acquisition, backed by Halozyme’s strong financial position, targets faster market delivery of breakthrough therapies and addresses unmet medical needs in oncology, neurology, and infectious diseases.

Pediatric COVID-19 vaccines under EUA could be at risk if pulled by HHS, unlike fully licensed vaccines.

The precision medicine market is projected to grow by USD 66.2 billion from 2024-2028, driven by the rising prevalence of chronic diseases and the increasing use of AI and ML. However, data privacy and security issues pose challenges. Key players include AbbVie Inc., Amgen Inc., AstraZeneca Plc, and others.

FDA grants Merck's sacituzumab tirumotecan (sac-TMT) breakthrough therapy designation for advanced non-squamous NSCLC with EGFR mutations, post-chemotherapy progression. This marks the first BTD for sac-TMT, an ADC developed with Kelun-Biotech, with Merck holding global marketing rights except in Greater China.

Dewpoint Therapeutics could receive up to $480 million in a partnership with Mitsubishi Tanabe Pharma for its ALS experimental medicine, which targets abnormal TDP-43 protein accumulations. Mitsubishi Tanabe, which already sells an ALS drug, will handle clinical development and commercialization if it licenses the program.

The generic pharmaceuticals market was valued at USD 424.98 billion in 2024 and is projected to reach USD 874.63 billion by 2033, driven by cost-effective medications, rising chronic disease prevalence, government support, and advancements in manufacturing technologies.

DelveInsight's report on the Respiratory Syncytial Virus (RSV) market forecasts trends and epidemiology in the U.S., EU4, UK, and Japan until 2034. Key companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies in development include Nirsevimab, RSVpreF Vaccine, and others. The market is expected to grow due to increasing incident cases and upcoming therapies, despite current treatment limitations.

Respiratory syncytial virus (RSV) market report by DelveInsight covers epidemiology, market forecast, and key companies like Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies include Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others.

Pharmaceutical supply chain waste includes expired medications, overproduction, inefficient distribution, packaging waste, and regulatory compliance issues. This leads to higher costs, environmental pollution, and medicine shortages. Strategies to reduce waste involve improved forecasting, sustainable packaging, and streamlined logistics. Industry collaboration is essential for sustainable practices, benefiting both public health and the environment.